Navigation path

The Central Asia Drug Action Programme (CADAP)

CADAP was launched in 2003 to support Central Asian countries in their anti-drug policies and is presently in its fifth phase of implementation which started in 2011. Unlike previous phases, the present phase of CADAP is implemented by a consortium of EU Member States, led by the German Gesellschaft für Internationale Zusammenarbeit (GIZ) and bringing together and directly transferring the EU’s best expertise.


What are the objectives of CADAP?

The objective of CADAP is to provide the Central Asia Countries with policy, legal and technical expertise and knowledge and thus facilitating the gradual adoption of EU and international good standards and practices on drug policies, prevention and demand/harm reduction methodologies.  The programme is developed in line with the EU Drug Strategy (2007-2012) and EU Central Asia Drug Action Plan (2009-2013) in “preventing and reducing drug use, dependence, and drug-related harms to public health and society.”

The specific goals of the programme are to encourage the adoption of EU good practices in the following areas:

  • Drug epidemiology: to establish a sustained capacity to analyse drug related data based on EMCDDA (European Monitoring Centre on Drugs and Drug Addiction) guidelines and standards and to assist improved and informed policy making in Central Asia;
  • Treatment of drug addiction in and outside prison: to offer the most modern treatment andrehabilitation services to inmates in prisons and in communities;
  • Prevention campaign in the media: to inform the population of the various types of risks of drug use and abuse (including drug- related diseases such as HIV/AIDS, hepatitis, etc)

What is CADAP 5?

In continuation of phase 4 of the programme, the implementation of CADAP 5 started in 2011 through a consortium of EU Member States with a budget of 5 million euro. Phase 5 of CADAP focuses mainly on demand reduction, while BOMCA 8 deals with supply and trafficking issues - given that many activities in the area of drug supply reduction are border-related. The current phase consists of four components:

DAMOS (implemented by ResAd, Czech Republic): To help the governments develop a better understanding of the drug trafficking, drug use, misuse and abuse situation in the Central Asian region, as well as the impacts and consequences of those complex phenomena. This will further result in improved policy decisions;

TREAT (implemented by Zentrum für interdisziplinäre Suchtforschung of Hamburg University (ZIS), Germany): To support the introduction of modern drug addiction treatment methods within the public health system and the prison system by promoting the development of comprehensive and integrated treatment methods that are able to deliver a continuum of care for drug users, including drug dependence treatment, HIV/AIDS and hepatitis B/C prevention and care, and reduction of the health and other social consequences;

MEDISSA (implemented by the National Bureau for Drug Prevention (KBPN), Poland): To help the governments prevent potential new drug users and reduce the number of current drug addicts by better informing the general public of the risks of drug usage;

OCAN (implemented by GIZ, Germany): To serve as the backbone with regard to project management issues of all three specific components. Furthermore, it provides the framework for partner coordination and project monitoring and implementation.

Main partners in the implementation of the programme comprise of State Drug Control Commissions, Ministries of Health, Ministries of Justice, Narcological centres, treatment units in prisons and rehabilitation centres. Final beneficiaries of the programme are vulnerable groups of drug users, youth, prisoners and prison staff, drug related medical workers, local communities and families of drug users.

Where can I find more information? For more information please visit the program website:

Last update: 31/08/2012 | Top